Kallikrein-kinin system: An emerging competitor or collaborator for VEGF in diabetic macular edema?

Diabetes

Volumn 64, Issue 10, 2015, Pages 3350-3352

  Murakami, Tomoaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KININ; VASCULOTROPIN A;

ANIMAL; DIABETES COMPLICATIONS; HUMAN; KALLIKREIN KININ SYSTEM; MACULAR EDEMA; METABOLISM; PHYSIOLOGY;

ANIMALS; DIABETES COMPLICATIONS; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; KININS; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84953319756     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0746     Document Type: Note

References (20)

1. Yau JWY, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35:556-564
2. Aiello LP, Avery RL, Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487
3. Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 2014; 37:893-899
4. Gardner TW, Antonetti DA, Barber A.J., LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(Suppl. 2):S253-S262
5. Antonetti DA, Klein R, Gardner TW Diabetic retinopathy. N Engl J Med 2012; 366:1227-1239
6. Browning DJ, Glassman AR, Aiello L.P., et al.; Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114:525-536
7. Wells JA, Glassman AR, Ayala A.R., et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372:1193-1203
8. Murakami T, Frey T, Lin C., Antonetti DA. Protein kinase Cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 2012; 61:1573-1583
9. Aveleira CA, Lin C-M, Abcouwer SF, Ambrósio AF, Antonetti DA. TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010; 59:2872-2882
10. Clermont A, Chilcote TJ, Kita T, et al Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011; 60:1590-1598
11. Gao BB, Clermont A, Rook S., et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through pre-kallikrein activation. Nat Med 2007; 13:181-188
12. Kita T, Clermont AC, Murugesan N, et al Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes 2015; 64: 3588-3599
13. Ikeda Y, Hayashi I, Kamoshita E., et al. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004; 64:5178-5185
14. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002; 277:2028-2032
15. Michell BJ, Griffiths JE, Mitchelhill K.I., et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999; 9:845-848
16. Orsenigo F, Giampietro C, Ferrari A., et al. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun 2012; 3:1208
17. Stone OA, Richer C, Emanueli C., et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol 2009; 29:657-664
18. Nakamura S, Morimoto N, Tsuruma K., et al. Tissue kallikrein inhibits retinal neovascularization via the cleavage of vascular endothelial growth factor-165. Arterioscler Thromb Vasc Biol 2011; 31:1041-1048
19. Otani A, Takagi H, Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82:619-628
20. Silvestre JS, Bergaya S, Tamarat R., Duriez M, Boulanger CM, Levy BI Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89:678-683